Novavax, Inc. (NVAX) vs Recursion Pharmaceuticals, Inc. (RXRX)
- Novavax, Inc. NVAX 11.26 −12.17%
- Recursion Pharmaceuticals, Inc. RXRX 3.47 −16.59%
Novavax, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Novavax, Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.2B and $2.1B). Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −15.1% against −61.6%. Novavax, Inc. has the higher net margin (−59.9% vs −945.9%) and the higher return on invested capital (0.00% vs −92.2%). Across the 17 metrics below, Novavax, Inc. leads on 14 and Recursion Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | NVAX | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.60% | 3.48% | 65.16% |
| Operating margin | (56.58%) | (991.72%) | 0.00% |
| Net margin | (59.87%) | (945.92%) | 0.00% |
| Free cash flow margin | (10.20%) | (645.82%) | 0.00% |
| Return on equity | 323.66% | (56.58%) | (56.36%) |
| Return on assets | (21.62%) | (41.26%) | (48.04%) |
| Return on invested capital | 0.00% | (92.22%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack